XP Chemistries AB

As of June 30, 2026, XP Chemistries AB carries a market capitalization of 53.22M, placing it among publicly traded companies globally. Its enterprise value stands at 43.51M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

XP Chemistries AB's next confirmed earnings release is scheduled for November 19, 2026.

As of June 30, 2026, XP Chemistries AB has 313.98M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 151.05, and the price-to-book ratio stands at 1.66.

These figures are as of June 30, 2026. The EV/Sales ratio of 135.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 43.51M versus a market cap of 53.22M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, XP Chemistries AB maintains a current ratio of 6.75, meaning it holds 6.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, XP Chemistries AB posted a negative return on equity (ROE) of -25.99, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -24.15, reflecting losses generated across the asset base. The company generates approximately 256,040.80 in revenue per employee across its workforce of 1.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.12 indicates how many times XP Chemistries AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, XP Chemistries AB recorded an income tax benefit of -2.33M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -11.89M and -9.56M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, XP Chemistries AB's stock has declined approximately 23.30% over the past 52 weeks. The 50-day moving average sits at 0.18, while the 200-day moving average is 0.18.

Over the twelve months ended June 30, 2026, XP Chemistries AB generated 320,051.00 in revenue and converted that into -9.56M in net income, yielding earnings per share of -0.03. EBITDA reached -10.17M, while operating income came in at -11.89M.

These figures are as of June 30, 2026. Total book value stands at 32.14M, with working capital of 10.17M providing operational flexibility.

XP Chemistries AB produced -11.68M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.30M in capital expenditures, free cash flow totaled -12.98M - equivalent to -0.05 per share.

Over the twelve months ended June 30, 2026, XP Chemistries AB posted a gross margin of 36.37, reflecting its pricing power and cost economics. The operating margin of -3,716.31 and net profit margin of -2,985.82 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -26.84: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -42.22, meaning XP Chemistries AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

XP Chemistries AB's most recent stock split took place on June 9, 2025 with a 73:75 split ratio.